Acasti is a biopharmaceutical innovator focused on the research, development and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil. Omega-3 fatty acids have extensive clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia. Market research commissioned by Acasti* suggests there is an important market need for an effective, safe and well-absorbing omega-3 therapeutic with a positive impact on the major lipids associated with cardiovascular disease risk. Since August 2008, Acasti is focused on addressing this important unmet market need. Source
No articles found.
ICU Medical, Inc. (Nasdaq:ICUI) develops, manufactures and sells innovative medica...
ICU Medical, Inc. (Nasdaq:ICUI) develops, manuf...
Forty Seven is a clinical-stage immuno-oncology company focused on developing nove...
Forty Seven is a clinical-stage immuno-oncology...
VBL Therapeutics is a publicly traded (NASDAQ: VBLT), late-stage clinical biopharm...
VBL Therapeutics is a publicly traded (NASDAQ: ...
Titan is a specialty pharmaceuticals company that develops therapeutics for select...
Titan is a specialty pharmaceuticals company th...
Join the National Investor Network and get the latest information with your interests in mind.